АНТИБІОТИКОРЕЗИСТЕНТНІСТЬ: МОЛЕКУЛЯРНІ МЕХАНІЗМИ ФОРМУВАННЯ ТА СУЧАСНІ СТРАТЕГІЇ МЕНЕДЖМЕНТУ
DOI:
https://doi.org/10.32782/2226-2008-2026-1-16Ключові слова:
антибіотикорезистентність, інфекція, імунний захист, фагоцити, раціональна антибіотикотерапіяАнотація
Актуальність. Антибіотикорезистентність (АБР) – найбільша загроза виживанню людини, що веде до втрати контролю над резистентними штамами бактерій. Метою роботи було продемонструвати патогенетичне підґрунтя АБР та можливості вирішення цієї проблеми. Для реалізації мети було проведено аналіз сучасних наукових публікацій щодо механізмів АБР та інноваційних підходів до її подолання. Результати. Основні механізми АБР передбачають знижену проникність цитолеми, ефлюксні помпи, модифікацію мішеней для антибіотиків (АБ), ферментативну інактивацію, горизонтальний перенос генів, участь імунної системи макроорганізму. Висновки. Контроль АБР – це раціональне використання АБ, оптимізація традиційної антибіотикотерапії, модуляція імунної відповіді, модуляція мікробіому та фаготерапія.
Посилання
World Health Organization. Antimicrobial resistance. Geneva: WHO; 2023. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.
European Antimicrobial Resistance Surveillance Network (EARS-Net) surveillance data for 2024 Antimicrobial resistance (AMR) reporting protocol 2025. http://ecdc.europa.eu/sites/default/files/documents/EARS-Net-reporting-protocol.pdf.
Habboush Y, Guzman N. Antibiotic Resistance. [Updated 2023 Jun 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. https://www.ncbi.nlm.nih.gov/books/NBK513277/.
European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU/EEA (EARS-Net). Annual Epidemiological Report 2023. Stockholm: ECDC; 2024. https://www.ecdc.europa.eu/en/publications-data/antimicrobialresistance-eueea-ears-net-annual-epidemiological-report-2023.
GBD 2021 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. Lancet. 2024.404(10459):1199–1226. DOI: 10.1016/S0140-6736(24)01867-1.
Martin JS, Genyn H. One Planet, One Health: Unpacking the Relationship between Antimicrobial Resistance & Climate Change. RM. Global health. 2024. https://rabinmartin.com/insights/unpacking-the-relationship-between-antimicrobialresistance-climate-change/?gad_source=1&gclid=Cj0KCQjw2N2_BhCAARIsAK4pEkUVgMTPoBBIjZ_l62jiikhg0UgPKvJsQ89WaNJCFXBPgWwsLk4klJ0aAoD_EALw_wcB.
About Antimicrobial Resistance. Centers for Disease Control and Prevention. 2024. https://www.cdc.gov/antimicrobialresistance/about/index.html.
Pailhoriès H, Herrmann JL, Velo-Suarez L, Lamoureux C, Beauruelle C, et al. Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome. European Respiratory Review. 2022;31(164):210259. DOI: 10.1183/16000617.0259-2021.
Schaefer M, Lui A, Ramesh P, Little C, Megli C. Determinants of antimicrobial resistance in a contemporary obstetrical cohort. American Journal of Obstetrics and Gynecology. 2022;226(1,S142). DOI: 10.1016/j.ajog.2021.11.250.
Chandra S, Broom A, Ridge D, et al. Treatment ’cultures’, sexually transmitted infections and the rise of antimicrobial resistance. Sociol Health Illn. 2025;47(1):e13832. DOI: 10.1111/1467-9566.13832.
Shah RA, Hsu JI, Patel RR, et al. Antibiotic resistance in dermatology: The scope of the problem and strategies to address it. Journal of the American Academy of Dermatology. 2022;86(6):1337–1345. DOI: 10.1016/j.jaad.2021.09.024.
Nguyen L. Antibiotic resistance mechanisms in M. tuberculosis: an update. Archives of Toxicology. 2016;90(7):1585–1604. DOI: 10.1007/s00204-016-1727-6.
Osei Sekyere J, Reta MA, Maningi NE, Fourie PB. Antibiotic resistance of Mycobacterium tuberculosis complex in Africa: A systematic review of current reports of molecular epidemiology, mechanisms and diagnostics. Journal of Infection. 2019;79(6):550–571. DOI: 10.1016/j.jinf.2019.10.006.
Liebenberg D, Gordhan BG, Kana BD. Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. Frontiers in Cellular and Infection Microbiology. 2022;12:943545. DOI: 10.3389/fcimb.2022.943545.
Floyd K, Glaziou P, Houben RMGJ, Sumner T, White RG, Raviglione M. Global tuberculosis targets and milestones set for 2016-2035: definition and rationale. International Journal of Tuberculosis and Lung Disease. 2018;22(7):723–730. DOI: 10.5588/ijtld.17.0835.
Chesnokova ММ, Bazhora YІ, Antonenko KО, Ostapchuk KV. The pecularities of tuberculosis, caused by Beijing strains. Odesa Medical Journal. 2022;1–2:55–59. DOI: 10.54229/2226-2008-2022-1-2-10.
Antonenko KO, Kresyun VI, Antonenko, PB. Mutations leading to drug-resistant Mycobacterium tuberculosis infection in Ukraine. Central European Journal of Medicine. 2010;5(1):30–35. https://doi.org/10.2478/s11536-009-0114-6.
Alvarez-Ainza ML, Fong-Coronado PA, Ruiz-Bustos E et al. Antibiotic resistance of ESKAPE group-microorganisms in health institutions from Hermosillo and Ciudad Obregon, Sonora, Mexico. Frontiers in Cellular and Infection Microbiology. 2024;14. DOI: 10.3389/fcimb.2024.1348093.
Benkő R, Gajdács M, Matuz, M, et al. Prevalence and antibiotic resistance of ESKAPE pathogens isolated in the emergency department of a tertiary care teaching hospital in Hungary: A 5-year retrospective survey. Antibiotics. 2020;9:1–17. DOI: 10.3390/antibiotics9090624.
Boucher HW, Talbot GH, Bradley JS, et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(1):1–12. https://doi.org/10.1086/595011.
Hu Y, Liu C, Shen, Z, et al. Prevalence, risk factors and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in patients from Zhejiang, China, 2008–2018. Emerging Microbes & Infections. 2020;9:1771–1779. DOI: 10.1080/22221751.2020.1799721.
Lone SA, Ahmad A. Candida auris-the growing menace to global health. Mycoses. 2019;62(8):620–637. DOI: 10.1111/myc.12904.
Denissen J, Reyneke B, Waso-Reyneke M, et al. Prevalence of ESKAPE pathogens in the environment: Antibiotic resistance status, community-acquired infection and risk to human health. International Journal of Hygiene and Environmental Health. 2022l;244:114006. DOI: 10.1016/j.ijheh.2022.114006.
Martinez JL. General principles of antibiotic resistance in bacteria. Drug Discovery Today. 2014;11:33–39. DOI: 10.1016/j.ddtec.2014.02.001.
Cox G, Wright GD. Intrinsic antibiotic resistance: mechanisms, origins, challenges and solutions. International Journal of Medical Microbiology. 2013;303:287–292. DOI: 10.1016/j.ijmm.2013.02.009.
Fajardo A, Martinez-Martin N, Mercadillo M, et al. The neglected intrinsic resistome of bacterial pathogens. PLoS One. 2008;3:e1619. DOI: 10.1371/journal.pone.0001619.
Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiology. 2018;4(3):482–501. DOI: 10.3934/microbiol.2018.3.482.
Motta SS, Cluzel P, Aldana M. Adaptive resistance in bacteria requires epigenetic inheritance, genetic noise, and cost of efflux pumps. PLoS One. 2015;10(3):e0118464. DOI: 10.1371/journal.pone.0118464.
Cag Y, Caskurlu H, Fan Y, et al. Resistance mechanisms. Annals of Translational Medicine. 2016;4(17):326. DOI: 10.21037/atm.2016.09.14.
Devi NSh, Mythili R, Cherian T, et al. Overview of antimicrobial resistance and mechanisms: The relative status of the past and current. The Microbe. 2024;3:100083. https://doi.org/10.1016/j.microb.2024.100083.
Manrique PD, Leus IV, López CA, et al. Predicting permeation of compounds across the outer membrane of P. aeruginosa using molecular descriptors. Communications Chemistry. 2024 Apr 12;7(1):84. DOI: 10.1038/s42004-024-01161-y.
Alenazy R. Drug Efflux Pump Inhibitors: A Promising Approach to Counter Multidrug Resistance in Gram-Negative Pathogens by Targeting AcrB Protein from AcrAB-TolC Multidrug Efflux Pump from Escherichia coli. Biology (Basel). 20228;11(9):1328. DOI: 10.3390/biology11091328.
Avakh A, Grant GD, Cheesman MJ, et al. The Art of War with Pseudomonas aeruginosa: Targeting Mex Efflux Pumps Directly to Strategically Enhance Antipseudomonal Drug Efficacy. Antibiotics (Basel). 2023;12(8):1304. DOI: 10.3390/antibiotics12081304.
Blair JM, Richmond GE, Piddock LJ. Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance. Future Microbiology. 2014;9:1165–1177. DOI: 10.2217/fmb.14.66.
Gill MJ, Simjee S, Al-Hattawi K, et al. Gonococcal resistance to β-lactams and tetracycine involves mutation in loop 3 of the porin encoded at the penB locus. Antimicrobial Agents and Chemotherapy. 1998;42:2799–2803. DOI: 10.1128/aac.42.11.2799.
Girlich D, Naas T, Nordmann P. Biochemical Characterization of the Naturally Occurring Oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrobial agents and Chemotherapy. 2004;48:2043–2048. DOI: 10.1128/AAC.48.6.2043-2048.2004.
Tao S, Chen H, Li N, et al. The Spread of Antibiotic Resistance Genes In Vivo Model. Canadian Journal of Infectious Diseases and Medical Microbiology. 2022;2022:3348695. DOI: 10.1155/2022/3348695.
Thacharodi A, Lamont IL. Aminoglycoside-Modifying Enzymes Are Sufficient to Make Pseudomonas aeruginosa Clinically Resistant to Key Antibiotics. Antibiotics (Basel). 2022;11(7):884. DOI: 10.3390/antibiotics11070884.
Vivekanandan KE, Kumar PV, Jaysree RC, Rajeshwari T. Exploring molecular mechanisms of drug resistance in bacteria and progressions in CRISPR/Cas9-based genome expurgation solutions. Global Medical Genetics. 2025 Feb 16;12(2):100042. DOI: 10.1016/j.gmg.2025.100042.
Blair JM, Webber MA, Baylay AJ, et al. Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiology. 2015;13(1):42–51. DOI: 10.1038/nrmicro3380.
Liu HY, Prentice EL, Webber MA. Mechanisms of antimicrobial resistance in biofilms. NPJ Antimicrobials and Resistance. 2024;2(1):27. DOI: 10.1038/s44259-024-00046-3.
Sun K, Yajjala VK, Bauer C, et al. Nox2-derived oxidative stress results in inefficacy of antibiotics against post-influenza S. aureus pneumonia. Journal of Experimental Medicine. 2016;213(9):1851–1864. DOI: 10.1084/jem.20150514.
Flannagan RS, Heit B, Heinrichs DE. Antimicrobial Mechanisms of Macrophages and the Immune Evasion Strategies of Staphylococcus aureus. Pathogens. 2015;4(4):826–868. DOI: 10.3390/pathogens4040826.
Chambers HF, DeLeo FR. Waves of Resistance: Staphylococcus aureus in the Antibiotic Era. Nature Reviews Microbiology. 2009;7(9):629–641. DOI: 10.1038/nrmicro2200.
Bertrand BP, Shinde D, Thomas VC, Whiteley M, Ibberson CB, Kielian T. Metabolic diversity of human macrophages: potential influence on Staphylococcus aureus intracellular survival. Infection and Immunity. 2024 Feb 13;92(2):e0047423. DOI: 10.1128/iai.00474-23.
Toniolo Ch, Dhar N, McKinney JD. Uptake‐independent killing of macrophages by extracellular Mycobacterium tuberculosis aggregates. EMBO Journal. 2023;42(9):e113490. DOI: 10.15252/embj.2023113490.
Dai X, Li Y, Zhang Y, et al. pH/H2O2 dual-responsive macrophage-targeted chitosaccharides nanoparticles to combat intracellular bacterial infection. Colloids and Surfaces B: Biointerfaces. 2025;248:114465. DOI: 10.1016/j.colsurfb.2024.114465.
da Silva RAG, Stocks CJ, Hu G, et al. Bosutinib Stimulates Macrophage Survival, Phagocytosis, and Intracellular Killing of Bacteria. ACS Infectious Diseases. 2024;10(5):1725–1738. DOI: 10.1021/acsinfecdis.4c00086.
Beam JE, Rowe SE, Conlon BP. Shooting yourself in the foot: How immune cells induce antibiotic tolerance in microbial pathogens. PLOS Pathogens. 2021;17(7):e1009660. DOI: 10.1371/journal.ppat.1009660.
Bustos-Hamdan A, Bracho-Gallardo JI, Hamdan-Partida A, Bustos-Martínez J. Repositioning of Antibiotics in the Treatment of Viral Infections. Current Microbiology. 2024 Oct 26;81(12):427. DOI: 10.1007/s00284-024-03948-7.
Ruiz Ramos J, Salavert Lletí M. Fosfomycin in infections caused by multidrug-resistant Gram-negative pathogens. Revista Española de Quimioterapia. 2019 May;32 Suppl 1(Suppl 1):45–54. PMID: 31131592; PMCID: PMC6555168.
Wright GD. Q&A: Antibiotic resistance: where does it come from and what can we do about it? BMC Biology. 2010;8:123. DOI: 10.1186/1741-7007-8-123.
Stallmach A, Steube A, Grunert P, et al. Fecal Microbiota Transfer. Deutsches Ärzteblatt International. 2020;117(3):31–38. DOI: 10.3238/arztebl.2020.0031.
Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World Journal of Gastrointestinal Pharmacology and Therapeutics. 2017;8(3):162–173. DOI: 10.4292/wjgpt.v8.i3.162.
Khomsiyah, Mohammad Zamroni, Adriano. Legal consequences of selling antibiotics drugs without doctor’s prescription in pharmacies. Journal Indonesia Law and Policy Review. 2024;6(1):22–31. https://doi.org/10.56371/jirpl.v6i1.302.
Guizi Ye, Hongyu Wu, Wei Wang, Hong Xie, Yan Xu, Shizhen Fang, Jiang Zhong, Qingshan Huang. Antibacterial and synergistic effects of enzybiotics in combination with antimicrobial peptides and outer membrane permeabilizers against Helicobacter pylori. FEMS Microbiology Letters. 2025;372:fnaf130. https://doi.org/10.1093/femsle/fnaf130.
Gajic I, Tomic N, Lukovic B, Jovicevic M, Kekic D, Petrovic M, Jankovic M, Trudic A, Mitic Culafic D, Milenkovic M, et al. A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges. Antibiotics. 2025;14(3):221. https://doi.org/10.3390/antibiotics14030221,
World Health Organization. Global action plan on antimicrobial resistance. WHO. 2021. https://www.emro.who.int/healthtopics/drug-resistance/global-action-plan.html,
Ha DR, Haste NM, Gluckstein DP. The Role of Antibiotic Stewardship in Promoting Appropriate Antibiotic Use. American Journal of Lifestyle Medicine. 2017;13(4):376–383. DOI: 10.1177/1559827617700824
